<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25954" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nondepolarizing Paralytics(Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>D'Souza</surname>
            <given-names>Ryan S.</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Porter</surname>
            <given-names>Burdett R.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Johnson</surname>
            <given-names>Rebecca L.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ryan D'Souza declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Burdett Porter declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rebecca Johnson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25954.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">It is necessary to prevent spontaneous muscular contraction and movement when performing surgical procedures. The introduction of muscle relaxants has revolutionized the practice of anesthesia. By the end of the 1950s, non-depolarizing, neuromuscular blocking drugs (NMBDs), d-tubocurarine, and gallamine were available.<xref ref-type="bibr" rid="article-25954.r1">[1]</xref>&#x000a0;Although these two relaxants are no longer in use, several newer NMBDs have emerged with safer side effect profiles over the last 20 years.<xref ref-type="bibr" rid="article-25954.r2">[2]</xref>&#x000a0;Non-depolarizing muscle relaxants&#x000a0;comprise the majority of clinically relevant neuromuscular blockers.<xref ref-type="bibr" rid="article-25954.r3">[3]</xref>&#x000a0;As their name indicates, they cause neuromuscular blockade without depolarizing the motor endplate.</p>
        <p>Non-depolarizing NMBDs work by competing with acetylcholine (Ach) for binding sites on nicotinic alpha subunits, blocking Ach from binding to the receptor. In some instances, they can also cause direct blocking of the inotropic activity of Ach receptors.<xref ref-type="bibr" rid="article-25954.r3">[3]</xref> They produce skeletal muscle relaxation for endotracheal intubation, reduce patient movement to optimize operating conditions,&#x000a0;and research has shown them to improve compliance with mechanical ventilation. Notably, there has yet to be a non-depolarizing NMBD developed that can work faster than the rapid-onset, depolarizing muscle relaxant succinylcholine. However, onset can accelerate by using larger initial dosing of some non-depolarizing NMBDs, for example, rocuronium. Since muscle relaxants lack analgesic or anesthetic properties, they are not for use without anxiolytic or hypnotic agents or in inadequately anesthetized patients due to increased risk of awareness during general anesthesia.<xref ref-type="bibr" rid="article-25954.r4">[4]</xref></p>
      </sec>
      <sec id="article-25954.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The Ach receptor housed within the post-junctional motor neuron cell membrane is comprised of five glycoprotein subunits: two alpha subunits and one each of beta, gamma, and epsilon. The arrangement of these subunits is in a cylindrical fashion, with the center containing an ion channel. When Ach binds to the two alpha-subunits, there is ion flow through the central ion channel with subsequent depolarization of the motor neuron. A non-depolarizing NMBD is a quaternary ammonium compound with positively-charged nitrogen that imparts an affinity to nicotinic Ach receptors. It only needs to bind one of the two alpha subunits to block Ach, thus preventing depolarization and producing muscle relaxation.<xref ref-type="bibr" rid="article-25954.r5">[5]</xref></p>
        <p>The two major structural classes of non-depolarizing agents include aminosteroid and benzylisoquinolinium. Recently, a third class has been developed, known as asymmetrical mixed-onium chlorofumarate (i.e., gantacurium).<xref ref-type="bibr" rid="article-25954.r6">[6]</xref><xref ref-type="bibr" rid="article-25954.r7">[7]</xref>&#x000a0;Examples of common aminosteroids include atracurium, rocuronium, vecuronium, and pancuronium. Common benzylisoquinolinium compounds include atracurium, cisatracurium, and mivacurium.<xref ref-type="bibr" rid="article-25954.r2">[2]</xref></p>
        <p>It remains unknown how the various drugs' structures affect their onset of action, and this&#x000a0;onset time appears to have an inverse relationship with drug potency.<xref ref-type="bibr" rid="article-25954.r8">[8]</xref></p>
      </sec>
      <sec id="article-25954.s3" sec-type="Administration">
        <title>Administration</title>
        <p>Weight-based dosing scalars are important because administration based on total body weight may result in overdose, while dosing based on ideal body weight may be sub-therapeutic. Recommendations are that non-depolarizing NMBDs are dosed based on ideal body weight to avoid prolonged paralysis.<xref ref-type="bibr" rid="article-25954.r9">[9]</xref>&#x000a0;Intravenous (IV) injection is the most common mode of delivery, although intramuscular (IM) injections may be possible for some non-depolarizing relaxants. The 95% effective dose (ED95) for NMBDs specifies the dose that produces 95% twitch depression in 50% of individuals. One to two times the ED95 dose for a particular non-depolarizing NMBD is the typical dose administered for intubation.<xref ref-type="bibr" rid="article-25954.r10">[10]</xref><xref ref-type="bibr" rid="article-25954.r11">[11]</xref></p>
        <p>A provider&#x02019;s choice of non-depolarizing NMBD depends on the desired speed of onset, duration of action, route of elimination, and side effects. For instance, muscle relaxants with a rapid onset (i.e., rocuronium) and brief duration may be desirable when endotracheal intubation is the reason for paralysis. On the other hand, a longer-acting agent like pancuronium may also produce intubating conditions in 90 seconds, but at the cost of pronounced tachycardia within the patient and a block that may be irreversible by an acetylcholinesterase inhibitor (for over 60 minutes), increasing the risk of postoperative pulmonary complications.<xref ref-type="bibr" rid="article-25954.r12">[12]</xref>&#x000a0;The table below displays the characteristics of various non-depolarizing NMBDs.<xref ref-type="bibr" rid="article-25954.r10">[10]</xref><xref ref-type="bibr" rid="article-25954.r11">[11]</xref></p>
        <p>Duration of action for some of the most commonly used agents:</p>
        <list list-type="bullet">
          <list-item>
            <p>Atracurium - 30 minutes or less</p>
          </list-item>
          <list-item>
            <p>Rocuronium - 45 to 70 minutes</p>
          </list-item>
          <list-item>
            <p>Pancuronium - 180 minutes or longer</p>
          </list-item>
          <list-item>
            <p>Vecuronium - 30 to 40 minutes</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25954.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>A non-immunologic histamine release occurs with the administration of benzylisoquinolinium compounds, typically mivacurium, atracurium, and doxacurium. This reaction is dose-related and affected by delivery rate, leading to positive chronotropy (H receptors), positive inotropy (H receptors), positive dromotropy (H receptors), skin flushing, and hypotension from peripheral vasodilation, and rarely bronchospasm. In fact, the non-depolarizing paralytic drug rapacuronium was withdrawn from the market as a result of its bronchospasm risk.<xref ref-type="bibr" rid="article-25954.r13">[13]</xref></p>
        <p>Several large-scale studies showed that NMBDs are the most common causative agents of anesthesia-related anaphylaxis.<xref ref-type="bibr" rid="article-25954.r14">[14]</xref><xref ref-type="bibr" rid="article-25954.r15">[15]</xref>&#x000a0;A prior history for anaphylaxis to one non-depolarizing NMBD also places a patient at an increased risk of cross-reactivity to another non-depolarizing NMBD.</p>
        <p>Other notable side effects are drug-specific. Pancuronium may cause tachycardia and hypertension due to its vagolytic mechanism on nodal cells mediated through muscarinic receptors. Laudanosine, a metabolite of atracurium and cis-atracurium, may accumulate and cause central nervous system stimulation with resultant seizures. Finally, in critically ill patients, long-term infusions of non-depolarizing NMBDs, particularly aminosteroids, can lead to profound weakness, termed critical illness polymyoneuropathy&#x000a0;(CIP).<xref ref-type="bibr" rid="article-25954.r16">[16]</xref></p>
        <p>Drug interactions may potentiate weakness from non-depolarizing muscle relaxants, including volatile anesthetics, local anesthetics, certain antibiotics (i.e., aminoglycosides), and magnesium. Physiological alterations may also potentiate paralysis, including respiratory acidosis, metabolic alkalosis, hypothermia, hypokalemia, hypercalcemia, and hypermagnesemia.<xref ref-type="bibr" rid="article-25954.r12">[12]</xref><xref ref-type="bibr" rid="article-25954.r17">[17]</xref><xref ref-type="bibr" rid="article-25954.r18">[18]</xref></p>
      </sec>
      <sec id="article-25954.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Prior hypersensitivity reactions and inadequate sedation are contraindications. The provider should also consider the metabolism of certain non-depolarizing NMBDs. Only pancuronium and vecuronium are metabolized to any significant degree by the liver (deacetylation), and thus caution is advised in hepatic failure. Vecuronium and rocuronium undergo biliary excretion and may accumulate to toxic levels in extrahepatic biliary obstruction. Relaxants that primarily undergo renal excretion (e.g., doxacurium, pancuronium, pipecuronium) should be avoided in renal failure. Atracurium and cisatracurium are unique NMBDs because they undergo spontaneous degradation via Hofmann elimination. The metabolism of mivacurium is via plasma pseudocholinesterase, similar to succinylcholine.<xref ref-type="bibr" rid="article-25954.r10">[10]</xref></p>
      </sec>
      <sec id="article-25954.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients who have received NMBDs require continuous pulse oximetry, cardiac monitoring, and end-tidal carbon dioxide monitoring. Peripheral nerve stimulation works to measure the depth of neuromuscular blockade. Typically, the ulnar and facial nerves are stimulated for monitoring. Neuromuscular blockade generally occurs more rapidly in laryngeal adductors, diaphragm, and masseter than in the adductor pollicis. Utilizing the nerve stimulator, the train of four (TOF) commonly helps assess blockade. It consists of four stimuli delivered at a frequency of 2 Hertz, and the ratio of the amplitude between the fourth to the first twitch response estimates the degree of the block. About 75% of Ach receptors become antagonized when the fourth twitch from TOF disappears, 85% receptor occupancy occurs when the third twitch disappears, 90% receptor occupancy occurs when the second twitch disappears, and 95% to 100% receptor occupancy occurs when the first twitch disappears. Adequate relaxation for surgery is present when 1 to 2 twitches of the TOF are present.<xref ref-type="bibr" rid="article-25954.r19">[19]</xref></p>
        <p>Other unique observations noted on the peripheral nerve stimulator when a non-depolarizing NMBD paralyzes a patient include a tetanic fade response, post-tetanic potentiation, potentiation of blockade by other non-depolarizing NMBDs, and antagonism of the block by acetylcholinesterase inhibitors. Since TOF is user-dependent and introduces a considerable margin of error, other modalities are also available, including acceleromyography, strain-gauge monitoring, and electromyography.<xref ref-type="bibr" rid="article-25954.r20">[20]</xref><xref ref-type="bibr" rid="article-25954.r21">[21]</xref></p>
        <p>After the reversal of neuromuscular blockade, a thorough evaluation of muscle strength is necessary. A TOF ratio of 0.9 is the usual recommendation, although the visual estimation of the TOF may not be accurate. A sustained tetanic response, the ability to lift one&#x02019;s head for 5 to 10 seconds, and good grip strength also suggest an adequate recovery.<xref ref-type="bibr" rid="article-25954.r22">[22]</xref></p>
      </sec>
      <sec id="article-25954.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Higher than recommended dosing, for example, based on total body weight, may cause prolonged paralysis beyond the time required for surgery; this may manifest with generalized weakness, decreased respiratory reserve, and even apnea.<xref ref-type="bibr" rid="article-25954.r23">[23]</xref>&#x000a0;The management of toxicity should focus on airway maintenance and respiratory support to maintain oxygenation until the NMBD undergoes metabolism. As mentioned, non-immunologic histamine release is dose-dependent and may lead to significant hypotension and possibly bronchospasm if utilizing toxic doses.</p>
        <p>Reversal of the NMBD can be done with anticholinesterase medications such as neostigmine or edrophonium. These anticholinesterase medications must be accompanied by an anticholinergic&#x000a0;drug such as glycopyrrolate or atropine to block the ACH activity at the&#x000a0;muscarinic receptors. Rocuronium and vecuronium specifically can be reversed with sugammadex, a selective relaxant binding agent (SRBA), offering a more rapid onset of reversal than neostigmine and without the muscarinic side effects. However, sugammadex may interfere with the efficacy of oral contraceptives, and an alternative form of contraception is recommended for the week following administration.<xref ref-type="bibr" rid="article-25954.r24">[24]</xref></p>
      </sec>
      <sec id="article-25954.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All interprofessional healthcare team members, including the nurse anesthetist, anesthesiologist, emergency medicine physician, and critical care specialist, who use neuromuscular blockers, must closely monitor all patients. These agents are usually administered to intubated patients, and hence, airway maintenance and respiratory support are vital. Muscle strength should undergo a regular assessment to determine if the drug's action has diminished. Pharmacists should also verify the agents and dosing when ordered outside the operating room and ensure no potential drug interactions exist with the patient's current medication profile. It is prudent to assign one&#x000a0;individual&#x000a0;whose sole responsibility is monitoring the patient's vitals and other signs associated with NMBD use. This would be the anesthesia provider inside the operating room. Any issues need to be reported to the surgeon or anesthesiologist immediately. Only through this type of collaborative care can the interprofessional healthcare team ensure that these agents are used safely and appropriately to direct patient outcomes optimally. [Level 5]</p>
      </sec>
      <sec id="article-25954.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25954&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25954">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25954/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25954">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25954.s10">
        <fig id="article-25954.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Properties of Non-Depolarizing Muscle Relaxants Contributed by Ryan D'Souza, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table__1.__Properties__of__Non-depolarizing__Muscle__Relaxants.__2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25954.s11">
        <title>References</title>
        <ref id="article-25954.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raghavendra</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Neuromuscular blocking drugs: discovery and development.</article-title>
            <source>J R Soc Med</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>95</volume>
            <issue>7</issue>
            <fpage>363</fpage>
            <page-range>363-7</page-range>
            <pub-id pub-id-type="pmid">12091515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sparr</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Beaufort</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Fuchs-Buder</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Newer neuromuscular blocking agents: how do they compare with established agents?</article-title>
            <source>Drugs</source>
            <year>2001</year>
            <volume>61</volume>
            <issue>7</issue>
            <fpage>919</fpage>
            <page-range>919-42</page-range>
            <pub-id pub-id-type="pmid">11434449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bufler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilhelm</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Parnas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Franke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dudel</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Open channel and competitive block of the embryonic form of the nicotinic receptor of mouse myotubes by (+)-tubocurarine.</article-title>
            <source>J Physiol</source>
            <year>1996</year>
            <month>Aug</month>
            <day>15</day>
            <volume>495 ( Pt 1)</volume>
            <issue>Pt 1</issue>
            <fpage>83</fpage>
            <page-range>83-95</page-range>
            <pub-id pub-id-type="pmid">8866353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fagerlund</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>LI</given-names>
              </name>
            </person-group>
            <article-title>Current concepts in neuromuscular transmission.</article-title>
            <source>Br J Anaesth</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>103</volume>
            <issue>1</issue>
            <fpage>108</fpage>
            <page-range>108-14</page-range>
            <pub-id pub-id-type="pmid">19546202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martyn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fagerlund</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>LI</given-names>
              </name>
            </person-group>
            <article-title>Basic principles of neuromuscular transmission.</article-title>
            <source>Anaesthesia</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>64 Suppl 1</volume>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">19222426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naguib</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brull</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Update on neuromuscular pharmacology.</article-title>
            <source>Curr Opin Anaesthesiol</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>483</fpage>
            <page-range>483-90</page-range>
            <pub-id pub-id-type="pmid">19384229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savarese</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>McGilvra</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Sunaga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Belmont</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Van Ornum</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Savard</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Heerdt</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011.</article-title>
            <source>Anesthesiology</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>113</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-73</page-range>
            <pub-id pub-id-type="pmid">20526187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kopman</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Klewicka</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kopman</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Neuman</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Molar potency is predictive of the speed of onset of neuromuscular block for agents of intermediate, short, and ultrashort duration.</article-title>
            <source>Anesthesiology</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>90</volume>
            <issue>2</issue>
            <fpage>425</fpage>
            <page-range>425-31</page-range>
            <pub-id pub-id-type="pmid">9952148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ingrande</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lemmens</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Dose adjustment of anaesthetics in the morbidly obese.</article-title>
            <source>Br J Anaesth</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>105 Suppl 1</volume>
            <fpage>i16</fpage>
            <page-range>i16-23</page-range>
            <pub-id pub-id-type="pmid">21148651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agoston</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vandenbrom</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Wierda</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of neuromuscular blocking drugs.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1992</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>94</fpage>
            <page-range>94-115</page-range>
            <pub-id pub-id-type="pmid">1551294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prielipp</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Coursin</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Applied pharmacology of common neuromuscular blocking agents in critical care.</article-title>
            <source>New Horiz</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-47</page-range>
            <pub-id pub-id-type="pmid">7922428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents.</article-title>
            <source>Korean J Anesthesiol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>500</fpage>
            <page-range>500-510</page-range>
            <pub-id pub-id-type="pmid">29046769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jakub&#x000ed;k</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rand&#x000e1;kov&#x000e1;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>El-Fakahany</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Dolezal</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors.</article-title>
            <source>BMC Pharmacol</source>
            <year>2009</year>
            <month>Dec</month>
            <day>28</day>
            <volume>9</volume>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">20038295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laxenaire</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Mertes</surname>
                <given-names>PM</given-names>
              </name>
              <collab>Groupe d'Etudes des R&#x000e9;actions Anaphylacto&#x000ef;des Peranesth&#x000e9;siques</collab>
            </person-group>
            <article-title>Anaphylaxis during anaesthesia. Results of a two-year survey in France.</article-title>
            <source>Br J Anaesth</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>87</volume>
            <issue>4</issue>
            <fpage>549</fpage>
            <page-range>549-58</page-range>
            <pub-id pub-id-type="pmid">11878723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hepner</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Castells</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis during the perioperative period.</article-title>
            <source>Anesth Analg</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>97</volume>
            <issue>5</issue>
            <fpage>1381</fpage>
            <page-range>1381-1395</page-range>
            <pub-id pub-id-type="pmid">14570656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Brull</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Bolton</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Brief review: Nondepolarizing neuromuscular blocking drugs and critical illness myopathy.</article-title>
            <source>Can J Anaesth</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>53</volume>
            <issue>11</issue>
            <fpage>1148</fpage>
            <page-range>1148-56</page-range>
            <pub-id pub-id-type="pmid">17079642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamberg</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Answine</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>A surgeon's assessment of inadequate neuromuscular antagonism in a case of prolonged neuromuscular blockade.</article-title>
            <source>J Anaesthesiol Clin Pharmacol</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>244</fpage>
            <page-range>244-7</page-range>
            <pub-id pub-id-type="pmid">23878451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waud</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Waud</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Interaction of calcium and potassium with neuromuscular blocking agents.</article-title>
            <source>Br J Anaesth</source>
            <year>1980</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>863</fpage>
            <page-range>863-6</page-range>
            <pub-id pub-id-type="pmid">7437224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srivastava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Reversal of neuromuscular block.</article-title>
            <source>Br J Anaesth</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>103</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-29</page-range>
            <pub-id pub-id-type="pmid">19468024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naguib</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kopman</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Lien</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brull</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>A survey of current management of neuromuscular block in the United States and Europe.</article-title>
            <source>Anesth Analg</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>111</volume>
            <issue>1</issue>
            <fpage>110</fpage>
            <page-range>110-9</page-range>
            <pub-id pub-id-type="pmid">19910616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Szokol</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Marymont</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Avram</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vender</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Nisman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit.</article-title>
            <source>Anesthesiology</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>109</volume>
            <issue>3</issue>
            <fpage>389</fpage>
            <page-range>389-98</page-range>
            <pub-id pub-id-type="pmid">18719436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hemmerling</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Brief review: Neuromuscular monitoring: an update for the clinician.</article-title>
            <source>Can J Anaesth</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-72</page-range>
            <pub-id pub-id-type="pmid">17197470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Szokol</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Marymont</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Avram</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vender</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit.</article-title>
            <source>Anesth Analg</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>107</volume>
            <issue>1</issue>
            <fpage>130</fpage>
            <page-range>130-7</page-range>
            <pub-id pub-id-type="pmid">18635478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25954.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corda</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Robards</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Sugammadex and Oral Contraceptives: Is It Time for a Revision of the Anesthesia Informed Consent?</article-title>
            <source>Anesth Analg</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>126</volume>
            <issue>2</issue>
            <fpage>730</fpage>
            <page-range>730-731</page-range>
            <pub-id pub-id-type="pmid">29200078</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
